Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RUTIVAC-1: RUTI in High-Risk NMIBC
NCT03191578Phase 1Completed
- Sponsor
- Archivel Farma
- Start
- Jun 2017
- Primary completion
- Jan 2020
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in non-muscle-invasive bladder cancer (NMIBC) comparing RUTI + BCG with Placebo + BCG (2 arms). Primary endpoints: Changes in the systemic Th1 immune response at 16 weeks, Changes in the local immune response in peritumoral tissue (Th1/Th2 ratio) at 16 weeks and 1 more. Started Jun 2017; status: completed.
02
Drugs
RUTI vaccine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT03191578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03191578.